NICE backs 'cost-saving' ambulatory monitoring for diagnosing hypertension

Updated NICE BP guidance recommending ambulatory monitoring before diagnosing primary hypertension will save the NHS millions of pounds, NICE believes.

NICE guidlines on ambulatory monitoring will lower the risk of overdiagnosis and so reduce GP workload and prescribing costs (Photograph: SPL)

In updated guidelines, NICE recommends that a diagnosis of primary hypertension should be confirmed using 24-hour ambulatory BP monitoring.

The new diagnostic criteria will lower the risk of overdiagnosis and so reduce GP workload and prescribing costs. A costing analysis presented alongside the guideline and published in The Lancet suggests that that the diagnostic criteria would be cost-saving within a year.

Within five years, a practice with 10,000 patients would save £2,000 a year and the NHS in England would be saving £10m a year, the analysis suggests.

Savings have been estimated based on a cost of £1,000 per ambulatory monitor. However, NICE expects prices of these devices to roughly halve as their use becomes more widespread.

Professor Bryan Williams of the University of Leicester, who helped developed the guidelines, said he expected that in some areas consortia, rather than practices, would buy ambulatory monitors.

NICE does not expect the guidelines to be followed immediately, but said it would expect the new recommendations to implemented within 'the next year or so'.

The revised recommendations contain no major changes to the treatment thresholds and targets, but the treatment algorithm has been simplified.

Birmingham GP Professor Richard McManus, who is professor of primary care cardiovascular research at University of Birmingham, also helped developed the guidelines. He said the guidelines marked ‘a significant change’ in the hypertension is diagnosed.

‘The use of ambulatory monitoring will ensure quicker and more accurate diagnosis that will be better for patients and better for the NHS,’ he said. ‘This represents an exciting advance which I am sure will be taken up internationally.’

The guidelines recommend a calcium channel blocker as the first pharmacological agent for patients aged over 55 years or of African or Caribbean family origin and an ACE inhibitor or angiotensin II receptor blocker (ARB) for patients under 55 years.

The updated recommendations, 'Clinical management of primary hypertension in adults', are available on the NICE website and replace NICE clinical guideline 34.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Just published

GP appointment

General practice delivered 342m appointments in 2022 - and lost nearly 500 GPs

General practice in England delivered around 342m appointments in total in 2022 with...

NHS sign

Local GPs unite to take over two practices run by hospital trust

GPs in Swindon have come together to take over two practices that had spent more...

Talking General Practice logo

Podcast: Why are junior doctors preparing to strike?

Talking General Practice speaks to BMA GP trainee committee chair Dr David Smith...


Practices face losing out on QOF income amid soaring demand

GP practices risk losing out on QOF income this year because sky-high demand for...

Nurse giving older man a COVID-19 vaccine

JCVI recommends targeted COVID-19 vaccination programme in 2023

People at higher risk of severe COVID-19 should be offered a booster vaccination...

Health and social care secretary Steve Barclay leaving number 10 Downing Street

Government sets out plans for 'major conditions' health strategy

The government is to set out a strategy to tackle six 'major' health conditions in...